Abstract: Embodiments of the present invention relates to an X-ray contrast agent. The X-ray contrast agent has an X-ray absorption the change of which between at least two different X-ray photon energy levels differs from the change in X-ray absorption of calcium between the at least two different X-ray photon energy level. Embodiments of the present invention also relates to an X-ray imaging method. Embodiments of the present invention additionally relates to an image reconstruction device. Embodiments of the present invention further relates to an X-ray imaging system.

Abstract: The present invention relates to the technical field of generating artificial contrast-enhanced radiological images.

Abstract: The present invention relates to a new class of compounds of general formula (I), to the metal chelates with a metal ion suitable for computed tomography thereof, to the Gd3+ chelate complexes thereof, to methods of preparing said compounds, and to the use of said compounds as contrast agents in diagnostic imaging, such as in magnetic resonance imaging (MRI) and computed tomography (CT).

Abstract: The present invention relates to pharmaceutical compositions comprising contrast agents, to methods for preparing said pharmaceutical compositions and to their use for radiological imaging.

Abstract: An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: A system, method, and computer program product for implementing a remote console for use in diagnostic imaging may include a user interface and/or at least one processor programmed and/or configured to: receive, from at least one of an injection system including an injector configured to deliver fluid to a patient and an imaging system including a scanner configured to scan the patient, procedure data associated with a procedure for the patient, at least one of the injection system and the imaging system including at least one further user interface different than the user interface, and the injection system being in communication with the imaging system; provide, via the user interface, a display, the display being generated based on the procedure data; receive, via the user interface, user input; and control, based on the user input, an operation of at least one of the injection system and the imaging system.

Abstract: The present disclosure relates to a liquid pharmaceutical formulation comprising a DO3A-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gd3+ ion, and R1, R2, R3, R4 and R5 are as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.

Abstract: An aqueous pharmaceutical composition including compound having the formula of tetragadolinium[4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: The present invention relates to systems, methods and computer programs for training and using a machine learning model to generate synthetic contrast-enhanced computed tomography images with the help of magnetic resonance contrast agents.

Abstract: Systems, methods, and computer programs disclosed herein relate to training and using a machine learning model to generate contrast-enhanced magnetic resonance images.

Abstract: Disclosed herein are systems and methods for generating artificial contrast-enhanced computed tomography (CT) images. An exemplary computer-implemented method involves receiving representations of an examination region of an examination object after administration of a contrast agent. The representations result from CT examination of the examination region at different X-ray energies. The method involves generating a representation of the contrast agent signals on the basis of the received representations (e.g., a signal intensity distribution brought about by the contrast agent in the examination region). The method involves generating a synthetic representation of the examination region comprising an ?-fold addition of the representation of the contrast agent signals to one of the received representations or to a virtual non-contrast agent representation of the examination region. ? is a negative or positive real number.

Abstract: The present disclosure relates to a liquid pharmaceutical formulation comprising a DO3A-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gd3+ ion, and R1, R2, R3, R4 and R5 are as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.

Abstract: The present invention relates to a new class of compounds of general formula (I), the Gd3+ chelate complexes thereof, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: The present disclosure relates to a liquid pharmaceutical formulation comprising a DOSA-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gd3+ ion, and R1, R2, R3, R4 and R5 are as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.

Abstract: The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

Abstract: An aqueous pharmaceutical composition including compound having the formula of tetragadolinium[4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10- tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Abstract: Systems, methods, and computer program products for determining different states of a contrast agent in different types of tissue can involve generating a magnetic resonance waveform for the contrast agent in an examination region that includes multiple tissue types. The contrast agent may have different relaxation-shortening effects in each different tissue type. The generated waveform may be compared to database waveforms to determine the concentration of the contrast agent in each tissue type in the examination region.

Abstract: Embodiments of the present invention relates to an X-ray contrast agent. The X-ray contrast agent has an X-ray absorption the change of which between at least two different X-ray photon energy levels differs from the change in X-ray absorption of calcium between the at least two different X-ray photon energy level. Embodiments of the present invention also relates to an X-ray imaging method. Embodiments of the present invention additionally relates to an image reconstruction device. Embodiments of the present invention further relates to an X-ray imaging system.

Abstract: An ensemble of at least two X-ray contrast agents includes X-ray contrast agent and a second X-ray contrast agent. The second X-ray contrast agent has an X-ray absorption whose change between at least two different X-ray photon energies differs significantly from the change of the X-ray absorption of the first X-ray contrast agent between the at least two different X-ray photon energies. An X-ray imaging method, an image reconstruction device, an X-ray imaging system are also disclosed.

Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.